[Comment] Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era
Salvage treatments for patients with Hodgkin's lymphoma who are refractory to or have relapsed on standard chemotherapy represent an unmet medical need. The main goal of salvage therapies before autologous stem cell transplantation (ASCT) is achievement of complete remission. Currently, the proportion of patients with relapsed or refractory Hodgkin's lymphoma achieving a complete response with standard second-line chemotherapy ranges from 17% to 76% in different studies, depending on how many lines of therapy patients had previously received or the presence of other risk factors.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Umberto Vitolo, Annalisa Chiappella Tags: Comment Source Type: research
More News: Cancer & Oncology | Chemotherapy | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants